San Antonio, TX., November, 23, 2011 – Keraplast Technologies., the provider of Replicine Functional Keratin advanced wound care products, today announced it has signed a distribution agreement with Marathon Medical (Commerce City, CO) and applied to be added to Marathon Medical’s existing Federal Supply Schedule (FSS) contract, administered by the Department of Veterans Affairs (VA) on behalf of the U.S. General Services Administration (GSA).
The arrangement allows Keraplast Technologies to expand the availability of its advanced Replicine Functional Keratin advanced wound care products in partnership with Marathon Medical throughout the entire federal healthcare system, the largest healthcare provider in the United States with over 1,300 Veterans health facilities, Department of Defense medical treatment facilities, Military Hospitals, Indian Health Service Hospitals and other government agencies.
“We are very honored to have secured this contract, which not only offers a multitude of opportunities to give patients access to our life saving products, but ensures that veterans and active soldiers have access to our revolutionary technology” said Bill Moore, Chief Operating Officer. “Our partnership with Marathon Medical offers a breadth of coverage within the VA system, as they have both the necessary experience and expertise in government agency sales.”
Keraplast Technologies with it’s Keragel, Keramatrix, and Kerasorb product line is changing the approach to wound care with Bioactive Barrier support to patients. Its groundbreaking technology is introducing a new paradigm in management of acute and chronic wounds as well as burn patients, by accelerating the healing process.
“Marathon Medical with Keraplast Technologies affords us a great opportunity to benefit our ongoing commitment to honor all fellow U.S. military veterans and active military personnel,” said John St. Leger, president, Marathon Medical, a Service Disabled Veteran Owned Small Business and verified by the Center for Veterans Enterprise (CVE). “The Revolutionary products that Keraplast Technologies offers the VA and Department of Defense, facilitates a dramatically improved way of treating patients suffering from chronic wounds successfully, therefore avoiding more serious complications, or lengthy hospitalizations.”
Access to Replicine Functional Keratin advanced wound care technology is now well established across the US health care market. Keraplast CEO Michael Espensen added “Kerex LLC” is our DME supplier that gives public and private health providers direct access to Keraplast wound care technology, as well as private individuals in need of advanced wound care, such as families living with Epidermolysis Bullosa. Home health providers in the south west can access our technology through our partner Homesite Liveability. Adding Marathon Medical to our partners to give VA health facilities access to Replicine is a significant addition and builds on our solid foundation in the US wound care market.”